《大行報告》高盛升石藥(01093.HK)目標價至25.8元 料研發可推動長期增長
高盛發表報告表示,石藥(01093.HK)上月底舉行了投資者日,闡述其主要研發計劃及檢視產品商業化的成就,該行亦見證了石藥的相關里程碑,包括公司加大對創新藥物的長期增長投入策略,更為多元及成熟的藥品研發平台,投資者更了解其更具透明性的產品管道,相信公司未來可受惠創新產品周期的佈局。
該行重申石藥「買入」投資評級,上調其未來12個月目標價,由18.9元升至25.8元,此按綜合方式作估值,維持對其今年每股盈利預測不變,同時升其2020年及2021年每股盈利預測各0.5%及1.5%,各至0.77及0.94元人民幣,反映公司潛在推出創新藥品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.